Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Marisa Mayorga"'
Autor:
Cristina Gómez-Ayerbe, Rosario Palacios, Marisa Mayorga, Miguel Nicolas Navarrete, Sergio Ferra, Inmaculada Ruiz, Coral Garcia, Manuel Castaño, Dolores Merino, Antonio Collado, Carmen Hidalgo-Tenorio, Marcial Delgado, Antonio Rivero, Jesús Santos
Publikováno v:
International journal of STDAIDS. 33(13)
Background Obesity among persons living with HIV (PLWH) has increased and weight gain after antiretroviral therapy (ART) can lead to metabolic disorders and impact survival. Our objective was to analyze weight and metabolic changes in HIV näive pati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::252074d770220bc7bc27204a2cd48849
https://pubmed.ncbi.nlm.nih.gov/36071543
https://pubmed.ncbi.nlm.nih.gov/36071543
Autor:
Rosario Palacios, Antonio Rivero, Isabel A. Pérez-Hernández, Marisa Mayorga, Fernando Lozano, Alfonso del Arco, Jesús Santos
Publikováno v:
Journal of the International Association of Providers of AIDS Care (JIAPAC). 15:189-193
We carried out a retrospective, multicenter study of a cohort of 298 asymptomatic HIV-infected patients who switched from a regimen based on 2 nucleoside reverse transcriptase inhibitors + protease inhibitor (PI)/nonnucleoside reverse transcriptase i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3436232e4e8a0449ce444e64a69efe62
https://doi.org/10.1177/2325957416629785
https://doi.org/10.1177/2325957416629785
Autor:
J. de la Torre, Mohamed Omar, Carmen Hidalgo-Tenorio, L. Muñoz‐Medina, Manuel Castaño, Jesús Santos, C Gálvez, Carmen M. González-Domenech, Rosario Palacios, Ana Belén Lozano, Marisa Mayorga
Publikováno v:
Journal of the International Association of Providers of AIDS Care, Vol 17 (2018)
Journal of the International Association of Providers of AIDS Care
Journal of the International Association of Providers of AIDS Care
Objectives: To analyze the efficacy and safety of dolutegravir/rilpivirine (DTG/RPV) in HIV-infected patients who switched from any other antiretroviral therapy (ART). Methods: Open-label, multicenter study including patients who switched to DTG/RPV
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7a9941fedff45f7faedc6943e6a53644
https://doaj.org/article/d44115df5f2a41bdae8eccdf8b5a6f9f
https://doaj.org/article/d44115df5f2a41bdae8eccdf8b5a6f9f
Autor:
Isabel A. Pérez-Hernández, A. Romero, M. A. Martínez, I. Pérez-Camacho, Marisa Mayorga, José Hernández-Quero, Rosario Palacios, M. Omar, José E. P. Santos, J. M. Romero, Julián Olalla, Carmen M. González-Domenech
Publikováno v:
Europe PubMed Central
We analysed the efficacy and safety of switching from a regimen based on nonnucleoside reverse transcriptase inhibitors (NNRTI) or integrase inhibitors (INI) to ABC/3TC + RPV in virologically suppressed HIV-infected patients. This multicentre, retros
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4f4fe1a62140be0c5bd54f16e8a8d38f
https://pubmed.ncbi.nlm.nih.gov/26879392
https://pubmed.ncbi.nlm.nih.gov/26879392
Autor:
Marisa Mayorga, Isabel A. Pérez-Hernández, Jesús Santos, Fernando Lozano, Carmen M. González-Domenech, Alfonso del Arco, Rosario Palacios, Antonio Rivero, Manuel Castaño
Publikováno v:
Journal of the International AIDS Society
Introduction : Rilpivirine (RPV) has a better lipid profile than efavirenz (EFV) in naive patients [1]. Switching to RPV may be convenient for many patients, while maintaining a good immunovirological control [2]. The aim of this study was to analyze
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::03b510d701aae58c098f6dfccf8410fb
https://doi.org/10.7448/ias.17.4.19795
https://doi.org/10.7448/ias.17.4.19795